rss
Br J Ophthalmol 2009;93:1351-1352 doi:10.1136/bjo.2009.158931
  • Original Article
  • Clinical science

Intravitreal bevacizumab therapy for neovascular age-related macular degeneration associated with poor initial visual acuity

  1. T Galbinur,
  2. E Averbukh,
  3. E Banin,
  4. I Hemo,
  5. I Chowers
  1. Department of Ophthalmology, Hadassah-Hebrew University Medical Center, and the Hadassah-Hebrew University School of Medicine, Jerusalem, Israel
  1. Correspondence to Dr I Chowers, Department of Ophthalmology, Hadassah University Hospital, POB 12000, Jerusalem 91120, Israel; chowers{at}hadassah.org.il
  • Accepted 17 April 2009
  • Published Online First 10 June 2009

Abstract

Aim: The aim of the study was to assess the efficacy of intravitreal bevacizumab injections for eyes with neovascular age-related macular degeneration (NVAMD) and poor initial visual acuity (VA).

Methods: A retrospective study of 44 consecutive treatment-naïve eyes with NVAMD who had initial VA of 0.1 decimal or worse, and that were treated with intravitreal bevacizumab injections, was undertaken. Charts, optical coherence tomography (OCT) and fluorescein angiograms (FAs) were reviewed for the purpose of the study.

Results: Mean lesion size was 3375 (SD 2116) μm, all lesions showed sub- or intra-retinal fluid in OCT, and active neovascularisation comprised 41.6 (SD 17.7)% (range 10–90%) of the lesion area according to FA. The mean follow-up time was 3.9 (SD 5.8) (range 1–21) months. Patients received a mean of 2.6 (SD 2.4) bevacizumab injections (range 1–14), and mean VA improved from 1.85 (SD 0.64) to 1.52 (SD 0.77) LogMAR (p = 0.002). At final examination, nine eyes (20%) had reduced VA, ten eyes (23%) had stable VA and 25 eyes (57%) had improved VA compared with baseline. Following treatment, mean macular thickness was reduced from 332 (SD 98) to 248 (SD 79) μm (p<0.0001).

Conclusions: Poor initial VA should not prevent use of bevacizumab in eyes with NVAMD. Selection of patients with signs of active neovascularisation based on ophthalmoscopy, OCT and FA may increase the likelihood of a favourable response to treatment.

Footnotes

  • Competing interests None declared.

  • Provenance and Peer review Not commissioned; not externally peer reviewed.

  • Ethics approval The study was approved by the institutional ethics committee.

  • iMARINA, Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovasular Age-Related Macular Regeneration.

  • iiANCHOR, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2009.158931v1
    2. 93/10/1351 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.